# US 2017/0304393 A1 · Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0304393 A1
- Document ID: US20170304393A1
- Status: Published application
- Kind: A1
- Application number: 15/516,078
- Filed: 2015-09-29
- Published: 2017-10-26
- Earliest claimed: 2014-10-01
- Assignees: Oxytone Bioscience B.V.
- Applicants: Oxytone Bioscience B.V.
- Inventors: Johannes Jan PLATTEEUW; Herman Jan Tijmen COELINGH BENNINK
- Web page: https://patentgrep.com/patent/US20170304393A1

## CPC

- A61K 38/095: Oxytocins; Vasopressins; Related peptides
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/205: {Polysaccharides, e.g. alginate, gums; Cyclodextrin}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/04: for inducing labour or abortion; Uterotonics
- A61P 15/06: Antiabortive agents; Labour repressants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides an orally disintegrating solid pharmaceutical dosage unit having a weight between 50 and 1,000 mg, said dosage unit consisting of: 1-100 wt. % of particles consisting of: 0.01-10 wt. % of a partus control substance selected from oxytocin, carbetocin, atosiban and combinations thereof; 5-70 wt. % of buffering agent; 20-94 wt. % of branched glucan; 0-70 wt. % of other pharmaceutically acceptable ingredients; 0-95 wt. % of one or more pharmaceutically acceptable excipients; the solid dosage unit comprising at least 5 μg of the partus control substance and having a pH buffer range of 3.5-5.7. The solid dosage unit of the present invention is easy to manufacture and perfectly suited for sublingual, buccal or sublabial administration. Furthermore, the dosage unit does not need to be stored and distributed under temperature controlled conditions.

## Claims

### Claim at position 1

-15. (canceled)

### Claim 16

An orally disintegrating solid pharmaceutical dosage unit having a weight between 50 and 1,000 mg and comprising:
(a) 1-100 wt. % of particles comprising:
(i) 0.01-10 wt. % of a partus control substance selected from oxytocin, carbetocin, and combinations thereof;
(ii) 5-70 wt. % of buffering agent;
(iii) 20-94 wt. % of branched glucan;
(iv) 0-70 wt. % of other pharmaceutically acceptable ingredients; and
(b) 0-99 wt. % of one or more pharmaceutically acceptable excipients;
wherein the solid dosage unit comprises at least 5 μg of the partus control substance and has a pH buffer range of 3.5-5.7.

### Claim 17 (depends on 16)

The dosage unit according to claim 16, wherein the buffering agent has a pH buffer range of 4.0 to 5.5.

### Claim 18 (depends on 16)

The dosage unit according to claim 16, wherein the buffering agent is selected from citrate, acetate, aspartate and combinations thereof.

### Claim 19 (depends on 16)

The dosage unit according to claim 16, wherein the branched glucan is hydrolyzed dextran with an average molecular weight in the range of 10-200 kDa.

### Claim 20 (depends on 16)

The dosage unit according to claim 16, wherein the partus control substance is oxytocin.

### Claim 21 (depends on 16)

The dosage unit according to claim 16, wherein the partus control substance is carbetocin.

### Claim 22 (depends on 16)

The dosage unit according to claim 16, wherein the particles contain 0.02-10 wt. % of divalent metal cation.

### Claim 23 (depends on 22)

The dosage unit according to claim 22, wherein the divalent metal cation and the partus control substance are present in the particles in a molar ratio between 5:1 and 1000:1.

### Claim 24 (depends on 23)

The dosage unit according to claim 23, wherein the divalent metal cation and the partus control substance are present in the particles in a molar ratio between 10:1 and 300:1.

### Claim 25 (depends on 16)

The dosage unit according to claim 16, wherein the particles contain 0.01-10 wt. % of a sequestrant.

### Claim 26 (depends on 16)

The dosage unit according to claim 16, wherein the one or more pharmaceutically acceptable excipients are selected from lactose, mannitol, xylitol, microcrystalline cellulose, croscarmellose sodium and combinations thereof

### Claim 27 (depends on 16)

A method of medical treatment, comprising buccally, sublingually or sublabially administering a dosage unit according to claim 16.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the medical treatment comprises treatment of postpartum hemorrhage.

### Claim 29 (depends on 16)

A method of preparing a solid dosage unit according to claim 16, comprising:
(a) providing an aqueous solution comprising the partus control substance, the buffering agent, branched glucan and optionally one or more other pharmaceutically acceptable ingredients;
(b) removing water from the aqueous solution, optionally after having sprayed the aqueous solution onto carrier particles, to produce solid particles containing the partus control substance, the buffering agent, the branched glucan and the optional one or more other pharmaceutically acceptable ingredients;
(c) mixing the particles with the one or more pharmaceutically acceptable excipients; and
(d) forming the mixture into a solid dosage unit.
